Full-Time

Digital Designer

Bio-Techne

Bio-Techne

1,001-5,000 employees

Purified proteins and reagents supplier

Compensation Overview

$55.6k - $91.5k/yr

Minneapolis, MN, USA + 1 more

More locations: Denver, CO, USA

Hybrid

Hybrid role; in-office Tuesday-Thursday.

Category
UI/UX & Design (2)
,
Required Skills
Drupal
UI/UX Design
Adobe Photoshop
Figma
Adobe Illustrator
Requirements
  • 3 to 5 years of experience in digital or graphic design with demonstrated web production work
  • Bachelor’s degree in Graphic Design, Web Design, Digital Media, or related field (or equivalent experience)
  • Proficiency in Adobe Creative Suite (Photoshop, Illustrator) and working knowledge of Figma, applied to both UI design contexts and digital asset creation
  • Strong hands-on experience with CMS platforms; Drupal 11 strongly preferred
  • Strong layout sensibility: grid, hierarchy, visual balance, and image integration within constrained environments
  • Clear communicator, able to articulate design rationale, present mockups to cross-functional stakeholders, and synthesize feedback into aligned, actionable direction
  • Comfortable facilitating design reviews, feedback sessions, and knowledge-sharing with peers
  • A robust portfolio demonstrating web design, digital collateral (email, social, landing pages), and real-world production execution
  • Strong attention to detail, organizational discipline, and production quality
Responsibilities
  • Produce visual mockups that give UI/UX and development teams a clear, realistic creative target when updating the design system
  • Document visual intent, including photography direction, spacing decisions, and brand rationale, so handoffs are clear and actionable
  • Design within known component and CMS constraints
  • Build and publish pages in Drupal CMS, assembling components, imagery, and content into polished, on-brand layouts
  • Apply strong layout judgment (hierarchy, spacing, image placement) within defined component constraints
  • Own the visual quality of every page you build: photography tone, typographic treatment, and overall brand fidelity
  • Prepare and optimize all image assets prior to CMS integration
  • Serve as the creative voice within UI/UX and development workflows, ensuring brand standards are upheld through execution
  • Translate creative direction into technical context and vice versa, and be fluent in both conversations
  • Surface visual quality issues early and bring solutions, not just observations
  • Conduct visual QA of live and staged pages against brand guidelines
  • Maintain and contribute to usage documentation and imagery references and templates for the broader team
  • Champion brand consistency across every digital touchpoint, from hero images to component-level asset crops
Desired Qualifications
  • Experience creating cross-functional guidelines or process frameworks for handoff and collaboration
  • Familiarity with Bynder (DAM) and Monday.com or similar workflow management tools
  • HTML/CSS literacy sufficient to understand layout constraints and communicate feasibility with developers
  • Genuine curiosity about AI tools and how they fit into a modern design workflow you've experimented and you're thinking critically about when to use them

Bio-Techne makes and sells life-science tools such as purified proteins, cytokines, growth factors, antibodies, immunoassays, and reagent solutions, along with ProteinSimple analytics and cell/gene therapy workflow technologies. Researchers use these products to produce, analyze, and quantify biomolecules and to carry out assays and workflow steps in cancer, immunology, and regenerative medicine. The company differentiates itself with a broad, integrated catalog and end-to-end support—from raw proteins to analytical solutions—delivered to a global customer base. Its goal is to be a leading provider of life-science tools that speed up discovery and development in healthcare and biology.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Minneapolis, Minnesota

Founded

1981

Simplify Jobs

Simplify's Take

What believers are saying

  • Large pharma delivered six consecutive quarters of double-digit growth.
  • China posted four straight quarters of positive organic growth.
  • Approximately 80% of revenue comes from consumables, supporting recurring sales.

What critics are saying

  • Emerging biotech weakness already reduced Protein Sciences demand and missed revenue estimates.
  • Two FDA Fast Track cell-therapy customers create order-timing concentration risk.
  • US academic funding cuts and diagnostics margin pressure can suppress near-term earnings.

What makes Bio-Techne unique

  • Bio-Techne combines reagents, instruments, and diagnostics across discovery to clinical workflows.
  • MauriceFlex and Refeyn create a four-hour bispecific antibody characterization workflow.
  • R&D Systems, Bio-Techne Spatial, and Bio-Techne Diagnostics unify three customer-focused brands.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Bio-Techne who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Short-term Disability

Long-term Disability

Pet Insurance

Legal Services

401(k) Company Match

Company Equity

Professional Development Budget

Paid Vacation

Paid Sick Leave

Paid Holidays

Parental Leave

Unlimited Paid Time Off

Hybrid Work Options

Employee Stock Purchase Plan

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Mar 26th, 2026
Bio-Techne tops Q4 research tools earnings with $295.9M revenue beat

Bio-Techne reported fourth-quarter revenues of $295.9 million, flat year-on-year but exceeding analysts' expectations by 2%. The life sciences company, which manufactures specialised reagents, instruments and services for research and diagnostic testing, delivered a strong quarter with an impressive beat on organic revenue estimates. Across the research tools and consumables sector, the 10 tracked companies reported satisfactory Q4 results, with revenues beating consensus estimates by 1.2%. However, share prices have struggled, falling an average of 18.6% since the latest earnings results. The subsector faces challenges including high R&D investment requirements, pricing pressures and vulnerability to research funding cycles, though opportunities exist in emerging fields like synthetic biology and laboratory automation.

PR Newswire
Mar 25th, 2026
Bio-Techne expands COMET spatial biology suite with new SPYRE Focus Panels and Amplification Kits

Bio-Techne Corporation has expanded its COMET spatial biology portfolio with new SPYRE Focus Panels and SPYRE Amplification Kits. The additions include Stroma and Vessel panels, alongside enhanced detection capabilities using sequential and enhanced layered amplification (seqLA) technology for low-abundance targets. The modular antibody panels feature validated antibodies with ready-to-use protocols, allowing researchers to reduce optimisation time whilst maintaining flexibility to incorporate their own markers. Updated HORIZON Image Analysis Software supports the new tools, streamlining tissue analysis workflows. The enhancements strengthen Bio-Techne's integrated spatial biology ecosystem for research and preclinical therapeutic development. Bio-Techne generated over $1.2 billion in net sales in fiscal 2025 and employs approximately 3,100 people worldwide.

Bio-Techne
Mar 25th, 2026
Bio-Techne advances Spatial Biology with modular expansion of COMET(TM) Suite.

Bio-Techne advances Spatial Biology with modular expansion of COMET(TM) Suite. March 25, 2026 * New SPYRE(TM) Focus Panels (Stroma and Vessel) broaden modular panel options, enabling deeper targeted insights in spatial biology workflows. * SPYRE(TM) Amplification Kits leverage sequential and enhanced layered amplification (seqLA(TM) technology enabling improved detection of low-abundance and challenging targets. * Enhancements strengthen the fully integrated COMET spatial biology ecosystem, supporting increased consumables adoption and panel expansion. MINNEAPOLIS, March 25, 2026 /PRNewswire/ - Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, today announced the expansion of its COMET(TM) solution portfolio with the addition of the new SPYRE(TM) Focus Panels and SPYRE(TM) Amplification Kits. Together, these strengthen the COMET technology modular, automated spatial biology workflow, delivering expanded flexibility, greater sensitivity, and enabling deeper, more focused interrogation of biologically meaningful data from initial assay design through final interpretation. To support these updates, new features of HORIZON(TM) Image Analysis Software have also been introduced, tailored for COMET hyperplex images using the new SPYRE tools, further streamlining tissue analysis. "Researchers need tools that make it easier to extract meaningful answers from complex tissue samples," said Steve Crouse, President of Bio-Techne's Diagnostics and Spatial Biology Segment. "Innovation is one of Bio-Techne's key differentiators, and SPYRE Focus Panels and SPYRE Amplification Kits reflect that strength. By incorporating these capabilities into the COMET Suite, we are giving researchers a more flexible, faster, and higher sensitivity workflow that enables researchers to achieve deeper insights with greater confidence." SPYRE(TM) Antibody Panels, including the newly introduced Stroma and Vessel Focused Panels, are modular antibody panels designed to enable flexible multiplex assay design while reducing optimization time. Panels leverage validated antibodies with ready-to-use protocols to streamline setup while maintaining flexibility to incorporate markers from a lab's own antibody library. SPYRE(TM) Amplification Kits use seqLA(TM) technology to improve the detection of low-abundance and difficult-to-detect targets. "Utilizing the pre-optimized SPYRE panel has not only increased the capacity of conventional multiplex immunofluorescence but also enabled a one-day experimental protocol," said Prof. Joanne Edwards, Professor of Translational Cancer Pathology, University of Glasgow. "The COMET workflow is straightforward and flexible, allowing us to easily integrate our own antibodies of interest. This technology provides insightful data, facilitating the simultaneous investigation of tumor and microenvironment cells within the same sample." Together, SPYRE Focus Panels and SPYRE Amplification Kits strengthen Bio-Techne's commitment to deliver a fully integrated, modular, and automated spatial biology ecosystem that accelerates research and preclinical therapeutic development. These innovations continue to empower researchers to generate richer data and deeper biological understanding from every tissue sample. ABOUT BIO-TECHNE: Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated over $1.2 billion in net sales in fiscal 2025 and has approximately 3,100 employees worldwide. For more information, visit www.bio-techne.com or follow the Company on social media at LinkedIn, X and YouTube. MEDIA CONTACTS: David Clair, Vice President Investor Relations [email protected] SOURCE Bio-Techne Corporation Released March 25, 2026

Yahoo Finance
Mar 11th, 2026
Bio-Techne added to Madison Mid Cap Fund amid research spending concerns

Bio-Techne Corporation, a life sciences research leader, was added to Madison Mid Cap Fund's portfolio in the fourth quarter of 2025, according to the fund's investor letter. The company manufactures and sells life science reagents, instruments and services, including over 6,000 proteins, 400,000 antibody types and 2,400 diagnostic assays. Madison Mid Cap Fund cited Bio-Techne's recurring revenue model, which comprises approximately 80% of its business, and expressed optimism about the new CEO's strategy to expand the company's leadership position in protein research. The fund purchased shares at what it considers a discount due to concerns about customer research spending. Bio-Techne reported $295.9 million in revenue for the second quarter of fiscal 2026, unchanged from the previous quarter. The company currently has a market capitalisation of $8.26 billion.

Pathology In Practice
Feb 17th, 2026
Bio-Techne's Ella platform gains CE-IVD marking

Bio-Techne's Ella platform gains CE-IVD marking. * February 17, 2026 Bio-Techne has announced that the Ella benchtop immunoassay platform has received CE-IVD marking and is now available for sale in the European Union. Ella is a compact, cartridge-based immunoassay system that delivers accurate biomarker results in under 90 minutes with minimal hands-on time. By simplifying the manual steps of traditional immunoassays, Ella reduces operator variability and provides high-quality, reproducible data suitable for both translational research and clinical applications. The platform is compatible with Simple Plex assays, which remain for research use only, and are powered by R&D Systems antibodies and proteins. With more than 390 analytes across neuroscience, immunology, oncology, and cell and gene therapy, the Simple Plex portfolio enables researchers to maintain consistency and data quality while working efficiently across a wide range of applications. "Ella's CE-IVD certification marks a significant step forward in advancing precision diagnostics," said Will Geist, President of Bio-Techne's Protein Sciences Segment. "It reflects our commitment to providing innovative tools that enhance clinical decision-making and improve patient outcomes." With CE-IVD marking now in place, hospitals, clinical laboratories, or other European organisations may use Ella as a validated platform for in-house test development, clinical trials, or other translational activities. Diagnostic assay developers may also develop clinical applications on the Ella CE-IVD validated platform. The certification enhances confidence in Ella's performance and supports Bio-Techne's long-term goal to advance precision medicine by providing dependable, standardized solutions for biomarker detection.